Calreticulin arms NK cells against leukemia. Academic Article uri icon

Overview

abstract

  • Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c+CD14+ cells.

publication date

  • October 9, 2019

Research

keywords

  • Leukemia
  • Rhabdomyosarcoma, Alveolar

Identity

PubMed Central ID

  • PMC6959451

Scopus Document Identifier

  • 85074046887

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2017.06.009

PubMed ID

  • 32002282

Additional Document Info

volume

  • 9

issue

  • 1